<DOC>
	<DOCNO>NCT00974363</DOCNO>
	<brief_summary>Subjects previously vaccinate 11 17 year age . This extension phase start 24 month vaccination subject vaccinate primary study enrol extension phase . No new subject enrol .</brief_summary>
	<brief_title>Study Evaluate Persistence Antibodies After Vaccination With Meningococcal Vaccine GSK 134612</brief_title>
	<detailed_description>Subjects previously vaccinate 11 17 month age GSK Biologicals ' meningococcal vaccine 134612 Mencevaxâ„¢ . This extension phase start 24 month vaccination subject vaccinate primary study enrol extension phase . No new study enrol . The subject 4 blood sample take : 24 , 36 , 48 60 month vaccination .</detailed_description>
	<mesh_term>Meningococcal Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<criteria>Subjects investigator believe and/or parent ( ) /guardian ( ) comply requirement protocol enrol study . A male female vaccinate meningococcal vaccine primary study 109069 . Written inform consent obtain parent ( ) /guardian ( ) subject write informed assent obtain subject subject le 18 year age , write informed consent obtain subject subject achieve 18th birthday . Healthy subject establish medical history clinical examination enter study . Use investigational nonregistered product ( drug vaccine ) within 30 day precede subject 's first visit . History meningococcal disease ; case document . Administration meningococcal polysaccharide meningococcal polysaccharide conjugate vaccine since previous vaccination study 109069 . Any confirmed suspected immunosuppressive immunodeficient condition , base medical history . Administration immunoglobulins and/or blood product within three month precede subject 's first visit . Bleeding disorder , thrombocytopenia , subject anticoagulant therapy Subjects withdraw consent contact followup study .</criteria>
	<gender>All</gender>
	<minimum_age>11 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>meningococcal vaccine GSK 134612</keyword>
</DOC>